Loxo Oncology shows high tumor response rates with second genetically targeted cancer drug
"Do we have the right drug for the right target? ... here, the answer seems to be yes."
Loxo Oncology has earned considerable buzz and a hefty stock market valuation for bringing a genomic-based approach to cancer drug development. The Connecticut biotech’s drugs target highly specific genetic mutations found in cancer cells, regardless of where in the body the tumor is located.
The first of Loxo’s experimental drugs, larotrectinib, has already demonstrated a strong cancer-killing ability in tumors with
